• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

44.58 +0.88 (+2.01%)
Streaming Delayed Price Updated: 2:32 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 221,975
Open 44.43
Bid (Size) 44.43 (1)
Ask (Size) 44.60 (1)
Prev. Close 43.70
Today's Range 44.05 - 44.75
52wk Range 19.45 - 53.27
Shares Outstanding 55,307,775
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'
July 09, 2025
Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Report Final Trades discussed SNV, IYF, NEE-PR, and GILD. 
Via Benzinga
Beyond The Numbers: 8 Analysts Discuss Kymera Therapeutics Stock
June 26, 2025
 
Via Benzinga

Performance

YTD
+9.0%
+9.0%
1 Month
+2.2%
+2.2%
3 Month
+32.3%
+32.3%
6 Month
+9.7%
+9.7%
1 Year
+2.2%
+2.2%

More News

Read More
Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday
June 26, 2025
Via Benzinga
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit
June 25, 2025
Via Stocktwits
What 6 Analyst Ratings Have To Say About Kymera Therapeutics
June 03, 2025
Via Benzinga
What's Next: Kymera Therapeutics's Earnings Preview
May 08, 2025
Via Benzinga
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
June 25, 2025
Via Benzinga
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
June 25, 2025
From Gilead Sciences, Inc.
Via Business Wire
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
June 12, 2025
Via MarketBeat
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
June 08, 2025
Via Benzinga
Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday
June 03, 2025
Via Benzinga
Disney To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
June 03, 2025
Via Benzinga
Kymera Therapeutics Soars After Multiple Analyst Upgrades; Retail Sentiment Turns Extremely Bullish
June 02, 2025
Via Stocktwits
Here are the top movers in Monday's session.
June 02, 2025
Via Chartmill
Which stocks are experiencing notable movement on Monday?
June 02, 2025
Via Chartmill
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
June 02, 2025
Via Benzinga
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
June 02, 2025
Via Benzinga
These stocks that are showing activity before the opening bell on Monday.
June 02, 2025
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 02, 2025
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
May 30, 2025
Via Benzinga
Friday's after hours session: top gainers and losers
May 30, 2025
Via Chartmill
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts
May 12, 2025
Via Benzinga
Earnings Scheduled For May 9, 2025
May 09, 2025
Via Benzinga
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?
April 27, 2025
Via Benzinga
Topics Artificial Intelligence
Why Kymera Therapeutics Stock Crushed it This Week
April 25, 2025
Via The Motley Fool

Frequently Asked Questions

Is Kymera Therapeutics, Inc. - Common Stock publicly traded?
Yes, Kymera Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Kymera Therapeutics, Inc. - Common Stock trade on?
Kymera Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kymera Therapeutics, Inc. - Common Stock?
The ticker symbol for Kymera Therapeutics, Inc. - Common Stock is KYMR on the Nasdaq Stock Market
What is the current price of Kymera Therapeutics, Inc. - Common Stock?
The current price of Kymera Therapeutics, Inc. - Common Stock is 44.58
When was Kymera Therapeutics, Inc. - Common Stock last traded?
The last trade of Kymera Therapeutics, Inc. - Common Stock was at 07/30/25 02:32 PM ET
What is the market capitalization of Kymera Therapeutics, Inc. - Common Stock?
The market capitalization of Kymera Therapeutics, Inc. - Common Stock is 2.47B
How many shares of Kymera Therapeutics, Inc. - Common Stock are outstanding?
Kymera Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap